期刊文献+

聚乙二醇化重组人白细胞介素-6经不同途径给药的药代动力学比较研究 被引量:2

Comparison of Pharmacokinetics PEG-rhIL-6 at Different Methods of Administration in Rat
下载PDF
导出
摘要 目的研究聚乙二醇化重组人白细胞介素-6不同给药途径的药代动力学。方法将大鼠分为皮下给药组、静脉给药组,每组各设3个剂量组。分别按40μg/kg、20μg/kg、3μg/kg给药。同位素示踪法用碘标记PEG-rhIL-6,采用TCA沉淀法检测放射性浓度,3P87软件判断房室模型并计算各种参数,并检测125I-PEG-rhIL-6皮下注射大鼠后不同时间的血药浓度。结果①静脉给药大鼠体内的血药浓度-时间曲线符合二房室模型,而皮下给药大鼠体内的血药浓度-时间曲线符合一房室模型;②皮下给药的达峰时间比静脉给药慢,但其有效血药浓度维持时间较静脉给药长;③皮下给药较静脉给药各时点血药浓度低。结论皮下给药毒性低,是一种安全可靠的给药方法;同时有效血药浓度维持时间较长,有利于治疗血小板减少症。 Objective To study the different pharmaeokinetics of PEG-rhlL-6 at different methods of administration in rat. Methods Rats were divided into two groups: one group administration of PEG-rhlL-6 via subcutaneous and the other via vein. Three different doses (40 μg/kg, 20μg/kg, 3 μg/kg) were given to different groups. Pharmacokinetics and distribution of PEG-rhIL-6 in rats were studied by 125I isotope tracing method. Pharmacokinetic analysis was performed using 3P97 computer software. Results Upon administration, PEG-rhIL-6 fitted to two-compartment model after administration via vein, while PEG-rhIL-6 fitted to one-compartment model after administration via subcutaneous. The Tmax of PEG-rhIL-6 after administration via vein was faster than via subcutaneous, but the concentration of PEG-rhIL-6 in blood were always relativity low at various time points and sustained a long time after administration via subcutaneous. Conclusion The method of administration via subcutaneous was better than via vein in this study.
出处 《四川动物》 CSCD 北大核心 2009年第2期259-261,共3页 Sichuan Journal of Zoology
关键词 聚乙二醇化重组人白细胞介素-6 药代动力学 不同给药方法 PEG-rhIL-6 pharmacokinetics different methods of administration
  • 相关文献

参考文献6

  • 1李安良.1989.应用生物药剂学与药物动力学(第二版)[M].中国医药科技出版社.
  • 2尹海林,何学令,包旭,刘学旭,杨光武.白细胞介素-6阻抗环磷酰胺致犬造血功能损伤的实验研究[J].生物医学工程学杂志,2005,22(4):798-801. 被引量:3
  • 3Drayer AL, Sibinga CT, Blom NR, et al. 2000. The in vitro effects of cytokines on expansion and migration of megakaryocyte progenitors[ J]. Br J Haematol, 109(4) : 776 -784.
  • 4Kishimoto T, Akira S, Taga T. 1992. Interleukin-6 and its receptor: a paradigm for cytokines[ J ]. Science, 258 (5082) : 593 - 597.
  • 5Markwell MAK. 1982. Anal[J]. Biochem,125:427 -432.
  • 6Sehmitz B, Wiekenhauser C, Thiele J, et al. 1999. Megakaryocyte induced fibroblast proliferation is enhanced by eostimulation with IL-6/ IL-3 and dependent on secretory and adhesion events [ J ]. Leuk Res, 23 ( 8 ) : 723 - 729.

二级参考文献8

共引文献2

同被引文献24

  • 1饶海林,张珂,曾海鹏,邓杰,张雪梅.大肠杆菌表达的人IL-6复性条件研究[J].微生物学免疫学进展,2007,35(3):27-30. 被引量:2
  • 2张珂,饶海林,曾海鹏,袁涛,张雪梅.PEG化重组人白细胞介素-6制品游离PEG测定方法的研究[J].微生物学免疫学进展,2007,35(3):35-38. 被引量:2
  • 3袁涛,王智杰,邓杰,张珂,李征,张雪梅.PEG-rhIL-6与rhIL-6在化疗模型小鼠中体内药效的比较研究[J].微生物学免疫学进展,2011,39(2):41-45. 被引量:2
  • 4张洁.生物标准物质的制备、发展及管理[J].中国生物制品学杂志,2007,20(8):630-632. 被引量:18
  • 5Ishibashi T, Shikama Y, Kimura H, et al. Thrombopoietic effects of interleukin-6 in long-term administration in mice [J]. Exp Hematol, 1993, 21 (5): 640-646.
  • 6Asano S, Okano A, Ozawa K, et al. In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets [J]. Blood, 1990, 75 (8): 1602-1605.
  • 7Bracho F, Krailo MD, Shen V, et al. A phase I clinical, phar- macological, and biological trial of interleukin-6 plus granulocyte- colony stimulating factor after Ifosfamide, Carboplatin, and Etopo- side in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/ IV con- stitutional toxicities [J]. Clin Cancer Res, 2001, 7 ( 1 ) : 58-67.
  • 8袁涛 王智杰 赵兆等.pET-11b-rhIL-6/BL21(DE3)512程菌高密度发酵工艺研究.四川大学学报:自然科学版,2008,45:279-282.
  • 9张雪梅,袁涛,张珂,等.白细胞介素-6聚乙二醇结合物及其制备方法和应用[P].中国,ZL200680013336.5.
  • 10Ishibashi T, Shikama Y, Kimura H, et al . Thrombopoietic effects of interleukin-6 in long-term administration in mice [ J ]. Exp Hematol, 1993,21 (5) :640-646.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部